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ABSTRACT 
ACCURACY OF ANTINUCLEAR ANTIBODY, ANTI-DOUBLE STRANDED 
DNA ANTIBODY, AND ANTI-HISTONE ANTIBODY TESTS IN THE 
SETTING OF ANTIPHOSPHOLIPID ANTIBODIES. David S. Wang, Linda K. 
Bockenstedt. Section of Rheumatology, Department of Internal Medicine, 
Yale University School of Medicine, New Haven, Connecticut. 
The antiphospholipid syndrome is a recently recogmzed clinical entity 
manifested by disease related to sequelae of thrombosis. Antiphospholipid 
antibodies associated with clinical disease can occur as a primary syndrome or 
in association with autoimmune diseases, especially systemic lupus 
erythematosus (SLE). Because serologic laboratory tests are important in the 
diagnosis and management of patients with SLE, this research intended to 
assess the reactivity of anticardiolipin antibodies (ACA) with substrates in 
commercially available lupus-related serologic tests for antinuclear antibody 
(ANA), double-stranded DNA (dsDNA), and histone antibodies. Sera from 
the Yale Rheumatology Diagnostic Laboratory were selected that had 
previously been reported as ACA positive. Sera were characterized for ACA 
by ELISA, ANA by HEp-2 cell immunofluorescence, anti-dsDNA antibodies 
by Crithidia immunofluorescence, and anti-histone antibodies by ELISA. 
ACA were adsorbed from ACA positive sera which also tested positive for 
ANA, anti-dsDNA, or histone antibodies, after which sera were re-assayed for 
these antibodies. After all serologic results were obtained, available charts 
were reviewed to correlate the serologic findings with the clinical 
presentation and diagnosis of patients whose sera had been analyzed. The 

results suggest that the presence of ACA in sera from patients without 
evidence of SLE can give rise to a false positive anti-dsDNA by Crithidia 
testing. 
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INTRODUCTION 
Background 
The antiphospholipid antibody syndrome (APS) is a clinical syndrome 
of recurrent venous and/or arterial thrombotic events that occurs in the 
setting of two principal types of autoantibodies: the lupus anticoagulant and 
anticardiolipin antibody (ACA).23 The syndrome was initially described in 
198610 in patients with underlying systemic lupus erythematosus (SLE)8 and 
therefore was originally thought to comprise a subset of SLE.26 However, it is 
now clear that the two can occur independently.17 The terms primary and 
secondary APS are used to distinguish between APS that occurs as a single 
disease entity and APS that arises in patients with other underlying disease 
processes, especially SLE.5'7'23 
Clinical Manifestations of APS 
Though the manifestations of APS are highly variable, the three 
principal presentations of patients with APS are arterial and venous 
thromboses in a young individual, recurrent pregnancy loss, or 
thrombocytopenia.1'11'22'23 
Arterial thrombotic events usually occur as discrete episodes involving 
single vessels. Arterial occlusions have been shown to involve vessels of all 
sizes, from large vessels such as the aorta to small capillaries. Stroke and 
other neurological events are perhaps the most striking clinical presentations 
of arterial occlusion due to APS. In one study, antiphospholipid antibodies 
were implicated in the pathogenesis of cerebral infarction in up to 7% of 
stroke patients.11 Other arterial thrombotic events result in myocardial 
infarctions, renovascular hypertension, gangrene, and blindness. There have 
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even been reports of intestinal, hepatic, and adrenal infarction leading to 
Addison's disease.16 
Venous thrombosis due to APS can produce equally serious sequelae. 
Disease manifestations include superficial thrombophlebitis, deep venous 
thrombosis, pulmonary embolus, Budd-Chiari syndrome, and renal vein 
thrombosis. A catastrophic occlusion syndrome associated with APS has been 
suggested by Asherson in which patients are critically ill and resemble those 
with disseminated intravascular coagulation.3 Although APS is a less 
common cause of venous occlusion than other hypercoagulable conditions, it 
is important to include APS in the differential diagnosis of a patient with 
otherwise unexplained venous thrombosis.8'16 
Recurrent fetal loss due to APS is secondary to placental infarction and 
other placental vascular anomalies associated with thrombosis. APS-induced 
pregnancy losses most commonly occur after the first trimester. Women 
with otherwise unexplained second or third trimester fetal loss or multiple 
recurrent fetal losses should undergo serological screening for 
antiphospholipid antibodies.8 As a result of increased recognition of the 
association between antiphospholipid antibodies and fetal loss, more women 
have completed successful pregnancies due to earlier diagnosis and 
interventional therapy. 
The final major manifestation of APS, thrombocytopenia, is frequent, 
but generally not a cause of clinically significant bleeding. These patients 
most often are diagnosed with APS after investigation of abnormal platelet 
counts obtained for other medical reasons.11 
Because the clinical manifestations of APS relate to thrombosis, APS 
can involve any organ system. Associated features such as livedo reticularis, 
hemolytic anemia, valvular heart disease with sterile vegetations, transverse 
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myelitis, pulmonary hypertension, migraine headache, and many others 
have been reported in patients with APS. Because these clinical features are 
present in a number of other diseases and the frequency of APS presenting 
with such manifestations is low, by themselves they rarely are useful clinical 
indicators of APS.8'16'22 
Antiphospholipid Antibodies 
Antiphospholipid antibodies comprise a group of antibodies that bind 
either directly to phospholipid or to plasma proteins that bind phospholipid. 
Antiphospholipid antibodies associated with thrombosis generally belong to 
the latter subset. Two autoantibodies associated with APS are the lupus 
anticoagulant and the anticardiolipin antibody (ACA).23 The lupus 
anticoagulant is defined by inhibition of the prothrombinase reaction in in 
vitro coagulation tests,5'28 and in some cases has been shown to be due to 
antibodies to prothrombin. Laboratory tests for the lupus anticoagulant 
include the activated partial thromboplastin time, the modified (dilute) 
Russell viper venom time,24 and the Kaolin Clotting Time. Prolongation of 
any of the above in vitro tests that is not corrected by adding normal sera (to 
account for clotting factor deficiencies) defines the presence of the lupus 
anticoagulant.23'27 
ACA is the other autoantibody that can be present in patients with 
APS.23 These autoantibodies are most commonly detected by ELISA using 
cardiolipin as a substrate.2'9 It has recently been shown, however, that the 
ACAs associated with clotting do not directly bind cardiolipin,14 but rather 
bind the plasma protein ^2-glycoprotein I or a lib-glycoprotein I-phospholipid 
complex.15'28 Although only weakly bound by ACA in plasma, 
immobilization of fi2-glycoprotein I by polystyrene or cardiolipin on ELISA 
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plates results in markedly enhanced binding of ACA to this protein.12 132- 
glycoprotein I therefore enhances the binding of autoimmune ACAs to 
cardiolipin as detected by ELISA.25 The mechanism by which antibodies to 132- 
glycoprotein I induce clotting is unknown, but 132-glycoprotein I has been 
shown to inhibit the intrinsic coagulation pathway.29 Because 132-glycoprotein 
I appears to be a necessary cofactor for pathogenic ACA binding, the binding of 
ACAs associated with infections, e.g. syphilis, in the absence of 132- 
glycoprotein I suggests that these infection-induced ACAs bind directly to 
phospholipid rather than plasma proteins that bind phospholipid.27'29 
Differences in primary binding antigens of ACAs offer one explanation for 
why infection-induced ACAs are not normally associated with clotting 
events. 
Pathophysiology 
Despite the wealth of knowledge concerning APS that has accumulated 
over the past decade, its pathophysiology and pathogenesis remain a mystery. 
It is unknown whether antiphospholipid antibodies directly lead to 
thrombosis or whether they represent a serologic marker for a 
hypercoagulable state.18 
Proposed mechanisms of action include the effects of antiphospholipid 
antibodies on different cells, clotting factors, and other proteins involved in 
the coagulation cascade. Suggested mechanisms of thrombosis include 
interference with 132-glycoprotein I activity, imbalance in the prostacyclin and 
thromboxane pathways, interference with antithrombin III, protein C, or 
protein S activity, and many others.8'18 Clearly, while there exists a strong 
association between antiphospholipid antibodies and thrombosis, a precise 
mechanism by which this occurs has not yet been established. 
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Differentiation between Primary APS and Secondary APS in Association with 
SLE: 
Although originally thought to be a subset of lupus patients, patients 
can develop APS in the absence of lupus or other autoimmune diseases. 
There are several autoantibodies seen in SLE that are helpful in confirming 
the diagnosis of SLE. Antinuclear antibodies (ANA) are an excellent 
screening test for SLE, with a sensitivity reported as high as 95%.19 However, a 
positive ANA is not specific for SLE; ANAs occur in other autoimmune 
diseases, chronic inflammatory processes, viral infections, and can be induced 
by several medications; in addition, ANAs occur in some normal 
individuals.6'13 Thus, although a useful screening test with a high predictive 
value if negative, presence of an ANA is not pathognomonic for SLE. 
Patients with SLE usually have ANAs with multiple specificities. For 
example, patients may have antibodies to both double-stranded DNA 
(dsDNA) as well as histones, proteins that bind DNA. The recognition that 
antibodies bind multiple antigens in a patient supports the diagnosis of an 
autoimmune disease process such as SLE. Anti-histone antibodies by 
themselves are not diagnostic of SLE. 
In contrast, 30-60% of patients with SLE have antibodies to native or 
dsDNA. Antibodies to native DNA are only found in SLE patients and are a 
diagnostic criterion for SLE. Although titers of anti-dsDNA antibodies do not 
always reflect SLE disease activity and are not necessarily helpful in following 
the clinical course of all patients with SLE, antibodies to dsDNA have been 
implicated in the pathogenesis of renal disease in SLE patients, and titers of 
high avidity anti-dsDNA antibodies correlate with renal disease activity.613'19 
Thus, the presence of anti-dsDNA antibodies carries significant 
diagnostic and prognostic value. There are several techniques for measuring 
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antibodies to dsDNA. The most commonly used assays in most diagnostic 
laboratories are the ELISA anti-dsDNA antibody assay and the Crithidia 
luciliae immunofluorescence assay. The ELISA anti-dsDNA antibody 
screening assay involves incubating sera on dsDNA coated plates and 
measuring quantitative binding of antibodies. The ELISA is the best 
screening assay, as it has the greatest sensitivity of all anti-dsDNA antibody 
tests. It measures, however, both low and high avidity anti-dsDNA 
antibodies as well as antibodies to denatured dsDNA (which may include 
ssDNA antibodies found also in non-lupus disorders) and therefore is less 
reliable as a specific marker for SLE or SLE renal disease.19'30 The Crithidia 
luciliae immunofluorescence assay is a test that measures anti-dsDNA 
antibodies in sera through the binding of antibodies to the kinetoplast on the 
protozoan Crithidia luciliae, which is a pure source of dsDNA, free of 
ssDNA. Although the Crithidia assay is less sensitive for anti-dsDNA 
antibodies than ELISA, it is a more useful test clinically because of its greater 
specificity, particularly for high avidity antibodies to dsDNA, which correlate 
with renal disease in SLE patients. A third technique, the Farr assay, is 
reputedly the most specific test for pathogenic anti-dsDNA antibodies; 
however, it is not widely available because it is expensive, employs 
radioactivity, and is technically more laborious.30 
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CASE PRESENTATION 
Recently, a previously healthy 19-year-old white male presented to 
Yale-New Haven Hospital with a pulmonary embolus and iri acute renal 
failure. Laboratory analysis revealed a strongly positive ACA. Further testing 
revealed a positive ANA and equivocally positive anti-dsDNA antibodies as 
measured by ELISA. Based on the findings of positive ANA and the 
borderline anti-dsDNA antibody test, the patient was given the clinical 
diagnosis of APS in association with SLE and probable lupus nephritis. 
To clarify laboratory tests, a rheumatology consultant suggested 
repeating the anti-dsDNA antibody tests, using the Crithidia luciliae 
immunofluorescence assay. Surprisingly, the Crithidia test, which is a less 
sensitive but more specific assay for anti-dsDNA antibody detection than the 
ELISA, was strongly positive, whereas an ELISA performed on the same sera 
was negative. Because the ACA was very high titer, it was postulated that the 
presence of ACA might contribute to the reactivity detected to dsDNA, 
yielding a false positive anti-dsDNA antibody by Crithidia. 
The ACA from this patient's sera was removed by affinity adsorption. 
Adsorption of ACA from the sera resulted in a loss of reactivity for dsDNA by 
all anti-dsDNA antibody tests on repeat testing, whereas a control serum from 
an ACA negative patient with known lupus nephritis and anti-dsDNA 
antibodies did not lose reactivity by Crithidia or ELISA after similar 
treatment. This supported the notion that the patient's ACA might have 
contributed to a false positive anti-dsDNA antibody test result. 
As noted above, histone antibodies frequently accompany anti-dsDNA 
antibodies in patients with SLE. Histones contain a charged region 
homologous to the phospholipid binding site on ^"glycoprotein I, a target of 
some ACAs. It was thus postulated that the high-titer ACA might also 
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influence histone antibody testing, although in this patient the anti-histone 
antibody test was negative. 
Review of the present medical literature revealed no information 
regarding the specificity of tests for ANA, anti-dsDNA antibodies, and anti¬ 
histone antibodies in the presence of ACA. The fact that this patient's anti- 
dsDNA antibody activity by Crithidia and ELISA disappeared following 
adsorption of ACA from his sera suggested that high-titer ACAs might lead to 
false positive anti-dsDNA and other autoantibody testing in ACA positive 
patient sera. The implications of this finding could be clinically significant 
and impact on patient diagnosis and management, especially considering that 
the presence of anti-dsDNA antibodies by Crithidia is regarded as a very 
specific laboratory finding supporting SLE as well as a marker associated with 
lupus nephritis. 
HYPOTHESIS 
Based on the case described, it is hypothesized that the presence of 
high-titer ACA could lead to false positive anti-dsDNA and other 
autoantibody testing important for the diagnosis of autoimmune diseases 
such as SLE. 
PURPOSE OF STUDY 
The purpose of this study was to determine whether the presence of 
ACA in sera affects standard commercially available laboratory tests for SLE: 
ANA by HEp-2 cell immunofluorescence, anti-dsDNA antibody by ELISA and 
Crithidia, and anti-histone antibody tests by ELISA. 
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OVERALL EXPERIMENTAL DESIGN 
Frozen sera specimens from the Yale Rheumatology Diagnostic 
Laboratory Sera Bank previously reported as positive for ACA were thawed 
and retested for ACA reactivity. Those sera that were ACA positive on 
retesting were further evaluated for ANA, anti-dsDNA antibody, and anti¬ 
histone antibody tests both before and after adsorption of ACA from the sera. 
Results were then statistically analyzed and conclusions were drawn 
regarding specificity of ANA, anti-dsDNA, and histone antibody tests in the 
presence of ACA. Upon completion of the study, historical features of the 
patient population were obtained by chart review to correlate with 
experimental findings. 
MATERIALS AND METHODS 
All methods described here were performed by the author. 
Selection of Patient sera: 
Sera from sixty-six patients were used for this study. Sera were selected 
by reviewing sample test results for ACA, ANA, and anti-dsDNA antibody 
from the Yale Rheumatology Diagnostic Laboratory Sera Bank over the past 
six years. Sera were selected from patients who had all been previously 
identified as having positive ACA in a standard ELISA assay. Sera included 
in the study were selected based on the presence of high-titer ACA IgG (>2 
times control) and/or the presence of concomitant positive ANA and anti- 
dsDNA antibody in addition to positive ACA. Sera were obtained in a 
fashion blinded to the underlying diagnosis or clinical features of the patients. 
Sera were at the onset aliquoted in triplicate to avoid the effects of repeated 
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freeze/thaw cycles on antibodies. Sera had been stored at -20°C for up to six 
years. 
Anticardiolipin Antibody Assay: 
Cardiolipin antigen (Sigma Chemical Company, St. Louis, MO) was 
diluted 116 pi in 10.4 ml of absolute ethanol, and 50 pi was aliquoted to each 
well of a Titertek 96 well flat plate (Flow Labs). Plates were kept uncovered at 
4°C overnight to allow for evaporation of ethanol reagent. Plates were 
washed three times with PBS with 0.02% azide (Sigma Chemical Company, 
St. Louis, MO) using an automated plate washer, then blocked with PBS and 
10% fetal calf serum (Gibco) with 0.02% azide for one hour at 20°C, covered. 
Plates were again washed three times as above, and 50 pi of 1:50 dilution 
patient sera or control sera was added to each well. Control sera included 
recently tested ACA positive sera as a positive control, normal human sera as 
a negative control, and Harris Standards (Louisville APL Diagnostics, Inc., 
Louisville, AL). Plates were incubated for two hours at 20°C, covered to 
prevent evaporation. Plates were washed as above, 50 pi of 1:1000 dilution 
goat anti-human IgG (X heavy chain specific) alkaline phosphatase labeled IgG 
(Southern Biotechnology Associates, Inc., Birmingham, AL) was added to 
each well, and plates were incubated two hours at 20°C, covered. Plates were 
washed as above and 50 pi of pNPP substrate (Sigma Chemical Company, St. 
Louis, MO) prepared according to pNPP kit instructions supplied by the 
manufacturer was added to each well. Plates were incubated covered in the 
dark at 20°C for 15 minutes (or until positive control IgG was at least 1.000 
OD) and read immediately on a Titertek Multiskan plate reader fitted with a 
405 nm filter. A standard reference curve was constructed using the Harris 
Standard reference controls, and the ACA reactivity of each sample was 
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reported in GPL units by comparing absorbance values against the standard 
curve. 
Adsorption of Anticardiolipin Antibodies from Sera: 
Cardiolipin-coated ELISA plates were prepared as described above. The 
first row of twelve wells (Row A on 96 well flat plates) was washed three 
times with PBS with azide, and 100 pi of patient sera diluted 1:10 in PBS was 
added to the first row of twelve wells along with negative controls. Plates 
were incubated for 30 minutes at 20°C, covered. The second row of wells 
(Row B on 96 well flat plates) was washed three times as above, and the 
diluted sera from the first row (Row A) was carefully transferred to the second 
row (Row B) using a multi-channel Titertek pipette taking caution to lose as 
little sera as possible between transfers. Following the transfer, 100 pi of 
blocking solution (10% FCS in PBS with 0.02% azide) was replaced into each 
well of the first row (Row A), and the plate was allowed to incubate for 30 
minutes. This procedure was repeated until the diluted patient sera was 
transferred to the eighth row of twelve wells (Row G) and the remaining 
wells contained blocking solution. The diluted patient sera was then 
transferred to another fresh pre-blocked cardiolipin coated plate and the 
adsorption procedure was repeated on the second plate. ELISA was 
performed on the plates from which the sera had been transferred in order to 
determine if ACA had been fully adsorbed out of patient sera by comparing 
with negative controls. Those patient sera which were still positive for ACA 
following adsorption from two plates were transferred to a third 96 well plate. 
Sera was transferred throughout the entire width of the third plate, and 
ELISA was performed on the third plate. 
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Antinuclear Antibody Assay (HEp-2 Cell Immunofluorescence): 
Antinuclear antibody indirect immunofluorescence assays were 
manufactured by Quidel from San Diego, California, USA. Tests were 
performed exactly as outlined in the manufacturer's instruction manual, with 
the exception that Evans blue counterstain was not used. Sera were initially 
diluted 1:40 and 1:160 in PBS. Further sample dilution was performed as 
needed. Forty gl of diluted sera was added to each well, along with two 
positive controls (homogeneous and speckled) and a negative control, all 
included in the kit. Slides were incubated in a humidified chamber for 20 
minutes, rinsed briefly with a stream of PBS, and washed in PBS for 10 
minutes at room temperature. Slides were then overlaid with fluorescein- 
conjugated goat anti-human IgG and incubated in a humidified chamber for 
20 minutes in the dark. Upon removal, slides were again washed as outlined 
above. Cover slips were then applied over a few drops of mounting media 
supplied by the kit. Lastly, slides were viewed using a Zeiss 
immunofluorescent microscope. 
Crithidia luciliae Immunofluorescence Assay: 
Crithidia luciliae anti-dsDNA assays were performed using CrithiDNA 
Anti-nDNA Antibody test kits manufactured by Antibodies Incorporated 
from Davis, California, USA. Tests were performed exactly as outlined in the 
manufacturer's instruction manual. Sera were diluted 1:10 in IFA-PBS 
(supplied by the kit) and ten pi of diluted test sera were added to each well on 
the substrate slides, along with both positive and negative controls included 
in the kit. Slides were incubated in a moist chamber for 30 minutes, rinsed 
briefly with a stream of IFA-PBS, washed for 10 minutes in IFA-PBS, and 
dipped in distilled water. Slides were then overlaid with fluorescent labeled 
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goat anti-human immunoglobulin and incubated for 30 minutes in the dark 
and washed again as outlined above. Cover slips were then applied over a 
few drops of buffered glycerol mounting media. Lastly, slides were viewed 
using a Zeiss immunofluorescent microscope. 
Anti-dsDNA ELISA: 
Anti-dsDNA ELISA kits were manufactured by Apotex Scientific, 
Incorporated, from Arlington, Texas, USA. Tests were performed exactly as 
outlined in the manufacturer's instruction manual. Sera were diluted 1:10 in 
Apotex sample diluent. One hundred pi of each prediluted sample sera or 100 
pi of Apotex anti-dsDNA reference controls were added to the appropriate 
wells. The plates with samples and controls were incubated for 60 minutes at 
room temperature. After decanting the contents of the plate, each well was 
washed three times with 200 pi of Apotex wash buffer per well, following 
which 100 pi of Apotex dsDNA conjugate was added to each well. The plates 
were allowed to incubate for 30 minutes at room temperature. The contents 
of the plate were decanted, and the plates were washed three times as 
described above, and 100 pi of Apotex substrate was added to each well. After 
another 30 minute incubation, 100 pi of Apotex stop solution was added to 
each well. The plates were immediately read on a Titertek Multiskan plate 
reader fitted with a 550 nm filter. A standard reference curve was constructed 
using the reference controls, and the anti-dsDNA antibody reactivity of each 
sample was reported in IU/ml by comparing absorbance values against the 
standard curve. 
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Anti-histone ELISA: 
Anti-histone ELISA kits were manufactured by Apotex Scientific, 
Incorporated, from Arlington, Texas, USA. Tests were performed exactly as 
outlined in the manufacturer's instruction manual. Sera were initially 
diluted 1:10 in Apotex sample diluent. One hundred pi of each prediluted 
sample sera or 100 pi of Apotex anti-histone reference controls were added to 
the appropriate wells. The plates with samples and controls were incubated 
for 60 minutes at room temperature. After decanting the contents of the 
plate, each well was washed three times with 200 pi of Apotex wash buffer per 
well, following which 100 pi of Apotex histone conjugate was added to each 
well. The plates were allowed to incubate for 30 minutes at room 
temperature. The contents of the plate were decanted, and the plates were 
washed three times as described above, and 100 pi of Apotex substrate was 
added to each well. After another 30 minute incubation, 100 pi of Apotex stop 
solution was added to each well. The plates were immediately read on a 
Titertek Multiskan plate reader fitted with a 550 nm filter. A standard 
reference curve was constructed using the reference controls, and the histone 
reactivity of each sample was reported in IU/ml by comparing absorbance 
values against the standard curve. 
Review of Patient Charts: 
Following the completion of all laboratory experiments, available 
patient charts in the Department of Medical Records at Yale-New Haven 
Hospital were reviewed. Attention was given to the discharge summaries to 
review clinical features and discharge diagnoses to determine whether 
patients had other disease states associated with their positive ACA. In 
addition, charts were reviewed to search for the reason that the ACA tests had 
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been ordered, e.g. to evaluate unexplained thrombosis or recurrent pregnancy 
loss. 
Statistical Analysis: 
Statistical analysis of data was performed after completion of all 
laboratory experiments. Statistical analysis was performed after discussion 
with James H. Jekel, M.D., M.P.H., Professor of Public Health, from the Yale 
University School of Medicine. 
RESULTS 
Selection of Sera 
Sixty-six sera were selected from patients who had previously tested 
positive for ACA by ELISA in the Yale Rheumatology Diagnostic Laboratory. 
Table 1 shows the original characteristics of the initial sample sera selected for 
the project. 

Table 1-Initial Sample Sera Characteristics 18 
Spec 
# 
Reported 
ACAlgG 
Orig 
Ctrl 
igG/ctl 
Ratio 
ANA 
(If avail) 
ANA Tit 
(If avail) 
AntiDNA 
(If avail) 
DNA Tit 
(If avail) 
1 399 37 10.78 
2 636 47 13.53 
3 338 47 7.19 Positive Negative 
4 1037 40 25.93 Negative Negative 
5 769 45 17.09 Positive Negative 
6 362 121 2.99 Positive 1:1280 Negative 
7 372 68 5.47 
8 579 61 9.49 
9 624 96 6.5 Positive 1:160 Positive 
1 0 635 72 8.82 Positive 1:2560 Positive 
1 1 336 58 5.79 Positive 1:320 Positive 1:80 
1 2 363 66 5.5 
1 3 428 81 5.28 
1 4 605 45 13.44 
1 5 1 94 69 2.81 Positive 1:640 Positive 1:10 
1 6 66 61 1.08 Positive 1:81920 Positive 1:1280 
1 7 672 73 9.21 Positive 1:640 Positive 
1 8 804 289 2.78 Positive 1:160 Negative 
1 9 288 137 2.1 Positive 1:51 20 Positive 
20 436 149 2.93 Negative Negative 
21 719 149 4.83 Negative Negative 
22 633 1 00 6.33 Positive 1:40 Negative 
23 432 1 54 2.81 
24 422 98 4.31 
25 1046 84 12.45 Positive 1:640 Negative 
26 837 82 10.21 
27 575 82 7.01 
28 325 82 3.96 Negative Negative 
29 786 108 7.28 
30 441 136 3.24 Negative Negative 
31 407 73 5.58 
32 896 135 6.64 Negative Negative 
33 519 102 5.09 Positive Negative 
34 419 105 3.99 Negative Negative 
35 399 154 2.59 
36 933 154 6.06 Negative Negative 
37 338 1 1 7 2.89 
38 610 210 2.9 
39 415 1 88 2.21 
40 407 1 09 3.73 
41 452 1 09 4.15 Positive 1:2560 Positive 
42 530 1 02 5.2 
43 348 1 02 3.41 
44 659 1 38 4.78 
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Spec 
# 
Reported 
ACA IgG 
Orlg 
Ctrl 
IgG/Ctl 
Ratio 
ANA 
(If avail) 
ANA Tit 
(If avail) 
AntiDNA 
(If avail) 
DNA Tit 
(If avail) 
45 375 60 6.25 Negative Negative 
4 6 1 75 1 30 1.35 Positive 1:1280 Positive 1:320 
47 388 1 66 2.34 
48 484 155 3.12 
49 642 106 6.06 Positive 1:20480 Negative 
50 1005 141 7.13 Positive 1:320 Negative 
5 1 491 213 2.31 
52 1 1 7 100 1.17 Positive 1:160 Positive 
53 532 350 1.52 
54 372 235 1.58 Positive 1:1280 Negative 
55 515 405 1.27 Positive 1:10240 Positive 1:40 
56 492 405 1.21 Positive 1:51 20 Positive 1:320 
57 564 125 4.51 Positive 1:5120 Positive 1:160 
58 1680 233 7.21 Positive 1:10240 Positive 1:160 
59 796 104 7.65 Positive 1:1280 Negative 
60 799 172 4.65 Positive 1:40 Negative 
61 871 276 3.16 Positive 1:40 Negative 
62 728 97 7.51 Positive 1:320 Negative 
63 449 294 1.53 Negative Negative 
64 333 150 2.22 
65 404 345 1.17 Positive 1:1280 Positive 1:80 
66 419 330 1.27 
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Anticardiolipin Antibody Assay 
Of the 66 sera tested for ACA at the beginning of the project, 58 were 
ACA positive (87.9%) and 8 were ACA negative (12.1%) on repeat testing. In 
order to assure that the originally reported ACA results were not different 
from the results obtained in this experiment, the reported results were 
compared with the experiment results by comparing the ACA IgG/Control 
IgG ratio. By using a standard paired t-test on the ACA IgG/Control ratios, the 
differences in the ACA IgG/Control ratio in the reported ACA and the 
experiment results were not statistically significant (p>0.5). Table 2 gives a 
comparison of the reported ACA and the experimental ACA results. Values 
obtained for ACA in the current study were reported in GPL units as 
determined by plotting individual results against a standard curve generated 
from the Harris Standard reference controls. Prior to last year, ACA results 
from the Yale Rheumatology Diagnostic Laboratory were not reported in GPL 
units, so a comparison based on Harris Standard GPL units could not be 
made. A representative graph of the standard curve typical of those used in 
the ELISA ACA assays is shown below: 
Standard ACA Curve Using Harris Standards 
i.i 
GH.Uhits: 
>80 High Positive 
20-80 Modeiate 
<20 Low Positive 
<10 Cut-Off 
0 10 20 3D 4D BD 40 7D B0 90 1D0 
EPL liartfa 

Table 2-Reported ACA vs. Pre-Adsorption AC A 21 
Spec 
# 
Reported 
ACA IgG 
Rep 
Ctrl 
IgG/Ctl 
Ratio 
Pre-Ads 
ACA IgG 
Pre-Ads 
Ctrl 
IgG/Ctl 
Ratio 
GPL 
Units 
1 399 37 10.78 1026 181 5.67 75 
2 636 47 13.53 978 181 5.4 68 
3 338 47 7.19 945 181 5.22 58 
4 1037 40 25.93 1149 181 6.35 >80 
5 769 45 17.09 879 181 4.86 50 
6 362 121 2.99 235 181 1.3 3 
7 372 68 5.47 1147 181 6.34 >80 
8 579 61 9.49 460 181 2.54 1 8 
9 624 96 6.5 610 161 3.79 26 ! 
1 0 635 72 8.82 795 161 4.94 43 
1 1 336 58 5.79 890 161 5.53 55 
1 2 363 66 5.5 880 161 5.53 53 
1 3 428 81 5.28 906 161 5.63 56 
14 605 45 13.44 867 161 5.39 52 
1 5 194 69 2.81 794 161 4.93 43 
1 6 66 61 1.08 226 161 1.4 3 
1 7 672 73 9.21 1145 161 7.1 1 >100 
1 8 804 289 2.78 1089 161 6.76 >100 
1 9 288 137 2.1 372 161 2.31 1 2 
20 436 149 2.93 857 161 5.32 50 
21 719 149 4.83 930 161 5.78 61 
22 633 100 6.33 932 161 5.79 61 
23 432 154 2.81 1056 161 6.56 93 
24 422 98 4.31 918 1 52 6.04 62 
25 1046 84 12.45 1007 1 52 6.63 >100 
26 837 82 10.21 970 152 6.38 8 5 
27 575 82 7.01 131 1 52 0.86 0 
28 325 82 3.96 504 1 52 3.32 1 8 
29 786 108 7.28 747 1 52 4.91 38 
30 441 136 3.24 360 1 52 2.37 1 1 
31 407 73 5.58 996 1 52 6.55 93 
32 896 135 6.64 871 1 52 5.73 55 
33 519 1 02 5.09 853 1 52 5.61 51 
34 419 1 05 3.99 245 1 52 1.61 5 
35 399 1 54 2.59 1 98 1 52 1.3 2 
36 933 1 54 6.06 897 1 52 5.9 58 
37 338 1 17 2.89 598 1 52 3.93 26 
38 610 210 2.9 805 1 52 5.3 45 
39 415 1 88 2.21 371 1 66 2.23 7 
40 407 1 09 3.73 1099 1 66 6.62 75 
41 452 1 09 4.15 1049 1 66 6.32 57 
42 530 1 02 5.2 1303 1 66 7.85 >100 
43 348 1 02 3.41 678 1 66 4.08 24 
44 659 138 4.78 1192 166 7.18 >100 

Table 2-Reported ACA vs. Pre-Adsorption ACA 22 
Spec 
# 
Reported 
ACA IgG 
Rep 
Ctrl 
IgG/Ctl 
Ratio 
Pre-Ads 
ACA IgG 
Pre-Ads 
Ctrl 
IgG/Ctl 
Ratio 
GPL 
Units 
45 375 60 6.25 1263 1 66 7.61 >100 
46 1 75 1 30 1.35 501 1 66 3.02 1 2 
47 388 1 66 2.34 838 1 66 5.05 33 
48 484 155 3.12 1 137 1 66 6.85 >100 
49 642 1 06 6.06 1117 1 66 6.73 >100 
50 1005 141 7.13 1202 1 66 7.24 >100 
51 491 213 2.31 620 1 66 3.73 1 8 
52 1 1 7 100 1.17 371 166 2.23 7 
53 532 350 1.52 706 1 66 4.26 24 
54 372 235 1.58 717 146 4.91 35 
55 515 405 1.27 298 146 2.04 7 
56 492 405 1.21 434 146 2.97 1 3 
57 564 1 25 4.51 1083 146 7.72 92 
58 1680 233 7.21 1192 146 8.16 >100 
59 796 1 04 7.65 1205 146 8.25 >100 
60 799 1 72 4.65 1048 146 7.18 77 
61 871 276 3.16 1232 146 8.44 >100 
62 728 97 7.51 1 145 146 7.84 >100 
63 
64 
449 294 1.53 660 146 4.52 32 
333 1 50 2.22 838 146 5.74 48 
65 404 345 1.17 365 146 2.5 1 0 
66 419 330 1.27 511 146 3.5 1 9 
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ANA, Anti-dsDNA, and Anti-Histone Results before ACA Adsorption 
Of the 66 sera tested for ANA by HEp-2 cell immunofluorescence, 45 
were ANA positive (68.2%) and 21 were ANA negative (31.8%). 
Of the 66 sera tested for reactivity to dsDNA, 12 tested were anti- 
dsDNA antibody positive (18.2%) and 54 were negative (81.8%) by Crithidia 
luciliae immunofluorescence. 
Of the 66 sera tested for anti-histone antibodies by ELISA, 25 were anti- 
histone antibody positive (37.9%) and 41 were negative (62.1%). Results were 
reported in anti-histone units/ml as determined by plotting individual 
results against a standard curve. The standard curve used for the anti-histone 
ELISA assays is shown below: 
Anti-histone Standard Curve 
1 2 a 10 20 X IDE 
AnlHferionv (UiHi/—1) 
1 iili iii kj 
Table 3 gives a summary of ACA, ANA, anti-dsDNA, and anti-histone 
results of patient sera prior to ACA adsorption. 

Table 3-ACA, ANA, Anti-dsDNA, and Anti-histone before Adsorption 24 
Spec # ACA GPL ANA Patrn Crithidia Histone U/ml 
1 Positive 75 Positive nuc Negative Positive 8 
2 Positive 68 Positive speck Negative Negative <2 
3 Positive 58 Positive speck Negative Negative 4 
4 Positive >80 Negative Negative Positive 21 
5 Positive 50 Positive speck,nuc Negative Negative <2 
6 Negative 3 Positive speck,nuc Negative Negative 3 
7 Positive >80 Negative Negative Positive 6 
8 Positive 1 8 Negative Negative Positive 7 
9 Positive 26 Positive horn Negative Negative 2 
1 0 Positive 43 Positive nuc Negative Negative 4 
1 1 Positive 55 Positive horn Negative Negative 3 
1 2 Positive 53 Negative Positive Negative 3.5 
1 3 Positive 56 Wk pos speck Negative Negative 4 
1 4 Positive 52 Positive hom Negative Negative 3 
1 5 Positive 43 Positive horn Negative Positive 8 
1 6 Negative 3 Positive hom Positive Positive >100 
1 7 Positive >100 Positive speck Positive Positive 1 2 
1 8 Positive >100 Positive hom,nuc Negative Negative 3 
1 9 Positive 1 2 Positive speck Negative Positive 8 
20 Positive 50 Negative Negative Positive 7 
21 Positive 61 Wk pos speck Negative Negative 5 
22 Positive 61 Wk pos speck Negative Positive 6 
23 Positive 93 Negative Positive Negative 4 
24 Positive 62 Positive speck Negative Negative 5 
25 Positive >100 Wk pos speck Negative Negative 3 
26 Positive 85 Negative Negative Positive 6 
27 Negative 0 Positive hom Negative Negative 4 
28 Positive 1 8 Negative Negative Positive >100 
29 Positive 38 Negative Negative Negative <2 
30 Positive 1 1 Negative Negative Negative 4 
31 Positive 93 Positive speck Negative Negative 3 
32 Positive 55 Negative Positive Negative 2 
33 Positive 51 Wk pos speck Positive Negative 3 
34 Negative 5 Negative Negative Negative <2 
35 Negative 2 Negative Negative Negative 2 
36 Positive 58 Positive hom Negative Negative <2 
37 Positive 26 Positive speck Positive Positive 25 
38 Positive 45 Positive speck Negative Positive 8 
39 Negative 7 Negative Negative Negative 5 
40 Positive 75 Negative Negative Negative 4 
4 1 Positive 57 Positive hom Negative Positive 6 
42 Positive >100 Positive hom Negative Negative <2 
43 Positive 24 Negative Negative Negative 4 
44 Positive >100 Negative Negative Negative <2 
45 Positive >100 Negative Negative Negative 2 

Table 3-ACA, ANA, Antl-dsDNA, and Anti-histone before Adsorption 25 
Spec # ACA GPL ANA Patrn Crithidia Histone U/ml 
46 Positive 1 2 Positive speck Positive Positive 21 
47 Positive 33 Negative Negative Negative 2 
48 Positive >100 Positive horn Negative Positive 8 
49 Positive >100 Positive horn Negative Negative 4 
50 Positive >100 Positive speck Negative Positive 1 9 
5 1 Positive 1 8 Wk pos nuc Negative Positive 20 
52 Negative 7 Wk pos speck Negative Negative 2 
53 Positive 24 Wk pos speck Negative Negative 2 
54 Positive 35 Positive speck,nuc Negative Negative 4 
5 5 Negative 7 Positive speck Positive Positive 6 
56 Positive 1 3 Positive rim Positive Positive 60 
57 Positive 92 Positive speck Positive Positive 9 
58 Positive >100 Positive speck Negative Positive 39 
59 Positive >100 Negative Negative Negative 3 
60 Positive 77 Wk pos speck Negative Negative 2 
61 Positive >100 Positive speck Negative Negative 2 
62 Positive >100 Wk pos speck Negative Negative 4 
63 Positive 32 Negative Negative Negative <2 
64 Positive 48 Positive hom Negative Positive 9 
65 Positive 1 0 Positive nuc Positive Positive 1 1 
66 Positive 1 9 Wk pos speck Negative Negative <2 
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Selection of Sera for ACA Adsorption 
After ANA, anti-dsDNA, and anti-histone assays were performed on 
sera, patient sera that had tested positive for ANA, anti-dsDNA, or anti- 
histone were selected for ACA adsorption. Sera that had tested negative for 
ACA by ELISA were not used for further study. 
Of the 66 patient sera initially selected by logbook review, 8 sera were 
negative for ACA on repeat study (Table 3: patients 6, 16, 27, 34, 35, 39, 52, and 
55) and an additional 9 sera that tested ACA positive were negative for ANA, 
anti-dsDNA, and anti-histone antibodies (Table 3: patients 29, 30, 40, 43, 44, 45, 
47, 59, and 63). Thus, 17 sera were excluded from analysis and a total of 49 sera 
were available for further analysis. 
Adsorption of ACA was performed on the 49 sera by the method 
described above. In addition, ACA adsorption was performed on five control 
sera which were ANA positive, anti-dsDNA antibody positive, but ACA 
negative. After repetitively transferring sera across two plates, 38 sera were 
negative for ACA by ELISA testing, and 11 sera were still positive for ACA. 
The 11 ACA positive sera were transferred to a fresh third plate and ACA 
adsorption was again performed to attempt loss of reactivity for ACA. 
Following completion of transfer on a third plate, 8 sera were ACA negative, 
and 3 sera were still ACA positive. The 3 ACA positive sera were excluded 
from further study. Further testing at this point was performed on the 46 
remaining ACA negative sera. 
Post ACA Adsorption Studies 
Antinuclear Antibodies: 
Forty of the 46 sera used for further analysis originally tested positive 
for ANA prior to ACA adsorption. ANA assays were performed on the 40 
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post adsorption sera previously positive for ANA. Five post adsorption sera 
that had previously tested negative to ANA were used as controls. Of the 40 
sera tested, 35 remained ANA positive (88%) and 5 became ANA negative 
(12%). In 4 out of 5 of the ANA negative sera, the ANA pattern prior to 
adsorption was speckled, though of extremely low-titer ANA at 1:40. Using 
McNemar's Chi Square Test with continuity correction, the differences in 
ANA reactivity following ACA adsorption were not statistically significant 
with 0.5<p<0.10. In some sera, however, ANA titer decreased and pattern 
changed, generally from speckled to homogeneous. Table 4 gives a 
comparison of ANA activity before and after ACA adsorption. 

Table 4-Comparison of ANA Before and After ACA Adsorption 28 
Spec 
# 
Prior to ACA Adsorption After ACA Adsorption Clinical Diagnoses 
(If Available) GPL ANA Pattern ACA ANA Pattern 
1 75 Positive nuc Neg Wk pos hom 
2 68 Positive speck Neg Wk pos speck 
3 58 Positive speck Neg Wk pos speck SLE,CVA,CAD,MI 
5 50 Positive speck,nuc Neg Positive speck,nuc 
9 26 Positive hom Neg Wk pos hom 
1 0 43 Positive nuc i Neg Wk pos hom 
1 1 55 Positive hom Neg Positive hom 
1 3 56 Wk pos speck Neg Wk pos speck 
1 4 52 Positive hom Neg Positive hom 
1 5 43 Positive hom Neg Wk pos hom 
1 7 >100 Positive speck Neg Positive hom 
1 8 >100 Positive hom,nuc Neg Wk pos hom,nuc 
1 9 1 2 Positive speck Neg Wk pos speck Preeclampsia,CVA 
21 61 Wk pos speck Neg Wk pos speck 
22 61 Wk pos speck Neg Negative 
24 62 Positive speck Neg Positive speck 
25 >100 Wk pos speck Neg Negative APS, Hyperthyroid 
31 93 Positive speck Neg Positive speck 
33 51 Wk pos speck Neg Negative 
36 58 Positive hom Neg Positive hom 
37 26 Positive speck Neg Positive speck 
38 45 Positive speck Neg Positive speck 
4 1 57 Positive hom Neg Positive hom 
42 >100 Positive hom Neg Negative 
46 1 2 Positive speck Neg Wk pos speck SLE 
48 >100 Positive hom Neg Positive hom 
49 >100 Positive hom Neg Wk pos hom 
50 >100 Positive speck Neg Wk pos hom SLE.ITP 
51 1 8 Wk pos nuc Neg Wk pos nuc SLE,CAD,HTN,Diabetes 
53 24 Wk pos speck Neg Negative 
54 35 Positive speck,nuc Neg Positive speck,nuc 
56 1 3 Positive rim Neg Positive hom SLE,ITP,Autoimm Hemol 
| 57 92 Positive speck Neg Positive hom SLE,APS 
58 >100 Positive speck Neg Positive speck 
60 77 Wk pos speck Neg Wk pos speck 
61 >100 Positive speck Neg Wk pos speck 
62 >100 Wk pos speck Neg Wk pos hom 
64 48 Positive hom Neg Wk pos hom Asthma, PE, Hemolysis 
65 1 0 Positive nuc Neg Positive nuc SLE,Myelitis,Renal Dis 
66 1 9 Wk pos speck Neg Wk pos speck Infertility, Ectopic Preg 
Abbreviations: nuc=nucleolar;speck=speckled;hom=homogeneous;CVA=Cerebrovascular Accident; 
CAD=Coronary Artery Disease;MI=Myocardial lnfarction;Wk pos=Weak Positive;Neg=Negative 

29 
Anti-dsDNA Antibodies: 
Ten of the 46 sera used for further study originally tested positive for 
anti-dsDNA antibodies prior to ACA adsorption. Crithidia anti-dsDNA 
studies were performed on the ten post adsorption ACA sera. Five post 
adsorption sera that had previously tested anti-dsDNA antibody negative 
were used as controls. Of the 10 sera, 6 remained anti-dsDNA antibody 
positive (60%) and 4 became negative (40%). Using Fisher's exact test, the 
differences in anti-dsDNA antibody reactivity before and after ACA 
adsorption were statistically significant with p=0.042. 
In addition, anti-dsDNA antibody testing was performed on the 10 sera 
using ELISA. Five sera were anti-dsDNA antibody positive (50%) and five 
sera were negative (50%) by ELISA testing. Statistical analysis was not possible 
on the post adsorption anti-dsDNA ELISA because anti-dsDNA ELISA was 
not performed prior to ACA adsorption. Table 5 gives a comparison of anti- 
dsDNA antibody activity before and after ACA adsorption. The standard 
curve used for the anti-dsDNA antibody ELISA assay is shown below: 
Anti-DNA Standard Curve 
Anti-DNA Units: 
<30 Negative 
30-50 Borderline 
50-300 Positive 
>300 Strong Positive 
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Anti-histone Antibodies: 
Twenty-three of the 46 sera used for further analysis originally tested 
positive for anti-histone antibodies. Due to limited resources, 19 of the 23 
sera were selected in a random fashion and were subsequently tested for 
antibodies to histone by ELISA. 
The 19 sera had all previously tested positive to anti-histone antibodies 
prior to adsorption. Of 19 sera tested, 15 remained anti-histone positive 
(79%), and 4 became anti-histone negative (21%). Results for anti-histone 
reactivity were reported in anti-histone units/ml. By using a standard two- 
tailed paired t-test, the differences in anti-histone reactivity before and after 
ACA adsorption were not statistically significant (0.5<p<0.10). Table 6 gives a 
comparison of anti-histone activity before and after ACA adsorption. 

32 Table 6-Comparison of AntiHistone Antibodies Before And After ACA 
____Adsorption__ 
Spec 
# 
Prior to ACA Adsorption After ACA Adsorption Clinical Diagnoses 
(If Available) GPL Histone Units/ml ACA Histone Units/m! 
4 >80 Positive 2 1 Neg Positive 6 CVA.SLE 
7 >80 Positive 6 Neg Negative 4 CVA.IBD 
8 1 8 Positive 7 Neg Positive 9 AIDS,CMV,PAN,HEP 
1 5 43 Positive 8 Neg Positive 5 Preeclampsia,CVA 
1 7 >100 Positive 1 2 Neg Positive 1 1 
1 9 1 2 Positive 8 Neg Negative 4 
20 50 Positive 7 Neg Negative 3 PIHJUGR 
28 1 8 Positive >100 Neg Positive 20 
37 26 Positive 25 Neg Positive 35 
38 45 Positive 8 Neg Positive 6 
46 1 2 Positive 2 1 Neg Positive 1 9 SLE 
48 >100 Positive 8 Neg Positive 7 
50 >100 Positive 1 9 Neg Positive 6 SLE,Idiopathic Thromb Purp 
5 1 1 8 Positive 20 Neg Positive 9 SLE,CAD,DM,HTN 
56 1 3 Positive 60 Neg Positive 50 SLE.Autoimmun Hemolysis,UP 
57 92 Positive 9 Neg Negative 3 SLEEPS 
58 >100 Positive 39 Neg Positive 25 
64 48 Positive 9 Neg Positive 9 Asthma,Hemolytic Anemia,PE 
65 1 0 Positive 1 1 Neg Positive 1 2 SLE,Myelitis,Renal Disease 
Dbreviations:Neg=Negative;CVA=Cerebrovascular Accident;IBD=lnflamm Bowel Dis;PAN=Pancreatitis;HEP=Hepatitis;PIH=Pregn 
iduced Hypertension;CAD=Coronary Artery Disease;DM=Diabetes;HTN=Hypertension;PE=Pulmonary Embolus 

Review of Patient Charts 
Following the completion of all laboratory experiments, available 
charts were examined on the original 66 sera. Charts were available from 33 
of the original 66 sera. Most of the sera for which charts were unavailable 
were from unhospitalized patients and/or patients whose sera was sent to the 
Yale Rheumatology Laboratory from other physicians or laboratories in the 
community. The underlying disease processes in select patients are 
demonstrated in Tables 4, 5, and 6. 
DISCUSSION 
Serological tests are important tools in the diagnoses of many clinical 
diseases. Often, as for APS and SLE, they can support a diagnosis that is 
suspected clinically. In addition, certain serological markers can predict 
clinical course, assess risk from disease, or monitor disease progress. For 
instance, anti-dsDNA antibodies by Crithidia are regarded as very specific 
serological markers in confirming the diagnosis of SLE; in addition, the 
presence of anti-dsDNA antibodies detected by Crithidia can correlate with the 
activity of lupus nephritis. Because serological tests are often relied upon to 
diagnose disorders, it is essential that they are interpreted correctly and 
limitations of tests are acknowledged. 
We assessed the specificity of serologic tests for SLE in the presence of 
ACA, as the latter autoantibody can be found in patients with SLE. A total of 
66 sera were used for this study. Before proceeding with the adsorption of 
ACA, the 66 sera were re-evaluated for ACA reactivity at the beginning of the 
experiment. Eight sera were negative for ACA in our hands, suggesting some 
technical variability with the current tests and those previously performed. 

Many sera had been stored for several years and it is possible that antibody 
denaturation could have contributed to the 8 negative ACA results, especially 
considering that the number of times that the sera had been thawed and 
frozen prior to this project was unknown. In most sera, however, the 
differences between the ACA IgG/Control ratios were not statistically 
significant, so the ACA ELISA technique used for this experiment was 
deemed acceptable and comparable to that of the Yale Rheumatology 
Diagnostic Laboratory. 
After ACA adsorption, differences were noted in ANA, dsDNA and 
histone testing. Five ANA positive sera (Specimens 22, 25, 33, 42, 53) became 
negative after ACA adsorption. In 4 out of 5 of these patients, the ANA 
reactivity prior to adsorption was extremely low-titer at 1:40 and in the 
experience of the Yale Rheumatology Laboratory generally of no clinical 
importance. Seven sera (Specimens 1, 10, 50, 56, 57, and 62) demonstrated a 
change in ANA pattern following ACA adsorption; in all cases, the pattern 
changed from either nucleolar or speckled into a homogeneous pattern. 
Although it is tempting to speculate that the ACA could contribute to 
nucleolar or speckled staining patterns in some circumstances, there was no 
obvious correlation with ACA titer or clinical diagnoses in these patient 
samples. 
Differences in anti-dsDNA antibody reactivity as determined by 
Crithidia immunofluorescence before and after adsorption of ACA were 
more striking. Table 4 lists the results of anti-dsDNA antibodies before and 
after ACA adsorption in parallel with clinical diagnoses. Seven out of 10 of 
the sera with positive anti-dsDNA antibodies prior to ACA adsorption had 
available patient charts. They were reviewed only after all laboratory work 
was completed, ensuring that the sera used during the experiment was 
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obtained and tested in a blinded fashion. Careful attention was focused on 
the 7 charts to look for underlying diagnoses. Patients 46, 56, and 65 all had a 
clinical diagnosis of SLE, low titer ACA, and demonstrated no change in anti- 
dsDNA antibody reactivity after ACA adsorption. Patient 57, also with an 
underlying diagnosis that included SLE, demonstrated a change in titer of 
anti-dsDNA antibodies after ACA adsorption, but was still positive for anti- 
dsDNA antibodies. This patient also had clinically apparent APS. 
Surprisingly, patients 12, 23, and 32—none of whom had an underlying 
diagnosis of SLE and were ANA negative—were anti-dsDNA antibody 
positive by Crithidia testing and lost this reactivity after ACA adsorption. Of 
particular note, patient 23 had high titer ACA (93 GPL Units) and high titer 
anti-dsDNA antibodies (>1:320), but following adsorption of ACA lost 
reactivity to anti-dsDNA antibodies. 
The loss of reactivity for Crithidia anti-dsDNA antibodies in patients 
12, 23, and 32 following ACA adsorption (all of whom had negative ANAs 
and no history of SLE from chart review) suggests that the reactivity to 
dsDNA might have been falsely positive due to the presence of ACA. This is 
intriguing given that the Crithidia test is considered the most specific test for 
anti-dsDNA antibodies; the dsDNA antibodies bind to the dsDNA kinetoplast 
present in the Crithidia organism. It is possible that in the ACA positive sera, 
immobilization of fi2-glycoprotein I by an antigen within the kinetoplast 
contributed to a positive interpretation of the Crithidia anti-dsDNA antibody 
assay. 
On the other hand, there was no loss of dsDNA reactivity for patients 
46, 56, 57 and 65. These patients all had an underlying diagnosis of SLE, 
suggesting that true autoantibodies to dsDNA are not affected by ACA 
adsorption. 
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In contrast to anti-dsDNA tests, there were no significant differences in 
anti-histone reactivity before and after adsorption of ACA. Although 4 of 19 
patient sera lost reactivity to anti-histone after ACA adsorption, a more 
accurate comparison using the anti-histone units/ml showed no significant 
changes before and after ACA adsorption. Two of the four patients that lost 
reactivity to anti-histone antibodies did not have SLE, and one had SLE with 
known APS. Thus, although the numbers are again low, the presence of 
ACA could contribute to anti-histone antibody positivity. 
Specificity of serological tests, including the Crithidia 
immunofluorescence and ELISA tests for antibodies to dsDNA, depends on 
the interactions between antibodies and the antigen driving their production. 
Several factors can influence the binding of antibodies that cross-react or 
nonspecifically bind to antigens in the assay. Antibodies bind to antigens 
through specific amino acid residues which in part give the antigen a 
characteristic charge and configuration. The noncovalent binding between 
antibody and antigen consists of a combination of hydrophobic forces, Van 
der Waals forces, hydrogen bonds, electrostatic bonds, and dipole interactions. 
The strength of binding is further influenced by the three-dimensional fit 
between the antigen and the antigen binding site on the antibody. Although 
the strongest binding occurs when shapes match exactly (which occurs with 
somatically mutated, high affinity antibodies), antigens can bind to antibodies 
when shapes match less perfectly; however, the strength of binding is 
decreased. Thus, there are physical and chemical properties of antigens and 
antibodies that influence binding.20'31 
In addition, there are general factors that can affect in vitro reactions 
between antigens and antibodies. The reaction conditions in the assays can 
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influence the strength of binding. The concentration of antigen and antibody, 
the pH and chemical composition of solutions, the size and charge of antigen 
and antibody, and the presence of other competing antibodies can all affect the 
noncovalent bond between antigen and antibody. Additionally, the three- 
dimensional fit between the antigen and antibody can be affected by reaction 
conditions. The antigen binding site on the antibody can undergo slight 
conformational change in order to accommodate the antigen. In an in vitro 
experiment, the structures of both antigen and antibody can be altered, thus 
affecting binding strength.2031 This is best exemplified by pathogenic ACAs, 
which bind fi2-glycoprotein I. Plasma levels of fi2-glycoprotein I are rarely 
affected by even high-titer ACA, as the conformation of 62-glycoprotein I in 
solution results in weak bonding affinity for ACA. In contrast, when plasma 
fi2-glycoprotein I is immobilized by phospholipid bound to plastic (as in the 
ACA ELISA) or by activated endothelium, the binding affinity of ACA 
increases by several orders of magnitude. These factors should be considered 
when using serological tests to identify antibodies in sera from patients. 
Weaknesses 
There are several weaknesses in this study. First, the study was only a 
pilot study employing a relatively small sample size. A larger study in the 
future might reveal more or less significant results. 
Although sera were initially aliquoted in triplicate in order to avoid 
repeated freezing and thawing, the effects of such cycles on reactivity to ACA, 
ANA, anti-dsDNA, and anti-histone antibodies cannot be determined. It is 
possible that freezing and thawing might have produced erroneous results. 
Furthermore, it is possible that the technique used for ACA adsorption might 
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have resulted in the inadvertent adsorption of other antibodies in addition to 
ACAs, which might account for the loss of reactivity to dsDNA. 
The experiment addresses whether the presence of high-titer ACA can 
yield false positive anti-dsDNA antibodies. However, it does not attempt to 
answer the converse, i.e. whether the presence of high-titer anti-dsDNA 
antibodies can give rise to a false positive ACA. 
While charts were obtained from patients on 50% of the sera, there 
were still 50% of sera for which no patient charts were available. It is difficult 
to determine precisely how the information from these patients might have 
affected the outcome of the experiment. 
CONCLUSION 
The newly emerging clinical spectrum of APS and its known 
association with SLE has made routine the screening of patients for both 
disorders. Our study suggests that some serologic tests, specifically the 
Crithidia luciliae immunofluorescence assay for anti-dsDNA antibodies, can 
be falsely positive in the presence of ACA. This finding underscores the need 
to interpret serologic tests in the context of the clinical situation. 
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